Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms

Genome Medicine

Volumn 1, Issue 5, 2009, Pages

  Goldin, Lynn R ^a   Björkholm, Magnus ^b,d   Kristinsson, Sigurdur Y ^b   Samuelsson, Jan ^c,d   Landgren, Ola ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c STOCKHOLM SÖDER HOSPITAL   (Sweden)

^d Swedish Myeloproliferative Disorder Study Group   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

CHRONIC DISEASE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GERM LINE; HAPLOTYPE; HETEROZYGOSITY; HUMAN; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; SHORT SURVEY; SOMATIC MUTATION;

EID: 77953431645     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm55     Document Type: Short Survey

References (18)

1. Darbary H, Stoler DL, Anderson GR: Family cancer syndromes: inherited deficiencies in systems for the maintenance of genomic integrity. Surg Oncol Clin N Am 2009, 18:1-17, vii.
2. Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL, Cario H, Pahl HL, Collins A, Reiter A, Grand F, Cross NC: JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009, 41:446-449.
3. Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL, Bass A, Marubayashi S, Heguy A, Garcia-Manero G, Kantarjian H, Offit K, Stone RM, Gilliland DG, Klein RJ, Levine RL: A germline JAK2 SNP is associated with predisposition to the developmentof JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 2009, 41:455-459.
4. Olcaydu D, Harutyunyan A, Jager R, Berg T, Gisslinger B, Pabinger I, Gisslinger H, Kralovics R: A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 2009, 41:450-454.
5. Tefferi A, Vardiman JW: Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008, 22:14-22.
6. Tefferi A, Gilliland DG: Oncogenes in myeloproliferative disorders. Cell Cycle 2007, 6:550-566.
7. Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchcomb DG, Edwards BK (Eds): SEER Cancer Statistics Review, 1975-2005. Bethesda: National Cancer Institute; 2008.
8. Sanchez S, Ewton A: Essential thrombocythemia: a review of diagnostic and pathologic features. Arch Pathol Lab Med 2006, 130:1144-1150.
9. Tefferi A, Elliott M: Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 2007, 33:313-320.
10. Tefferi A, Gangat N, Wolanskyj AP, Schwager S, Pardanani A, Lasho TL, Mesa R, McClure RF, Li CY, Hanson CA: 20+ years without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis. Eur J Haematol 2008, 80:386-390.
11. Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, Orlandi E, Arcaini L, Brusamolino E, Pascutto C, Cazzola M, Morra E, Lazzarino M: Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004, 117:755-761.
12. Hoffman R, Rondelli D: Biology and treatment of primary myelofibrosis. Hematology Am Soc Hematol Educ Program 2007, 2007:346-354.
13. Schaub FX, Jager R, Looser R, Hao-Shen H, Hermouet S, Girodon F, Tichelli A, Gisslinger H, Kralovics R, Skoda RC: Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. Blood 2009, 113:2022-2027.
14. Rumi E: Familial chronic myeloproliferative disorders: the state of the art. Hematol Oncol 2008, 26:131-138.
15. Rumi E, Passamonti F, Picone C, Della Porta MG, Pascutto C, Cazzola M, Lazzarino M: Disease anticipation in familial myeloproliferative neoplasms. Blood 2008, 112:2587-2588; author reply 2588-2589.
16. Bellanné-Chantelot C, Chaumarel I, Labopin M, Bellanger F, Barbu V, De Toma C, Delhommeau F, Casadevall N, Vainchenker W, Thomas G, Najman A: Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 2006, 108:346-352.
17. Landgren O, Goldin LR, Kristinsson SY, Helgadottir EA, Samuelsson J, Bjorkholm M: Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. Blood 2008, 112:2199-2204.
18. Kramer A: JAK2-V617F and BCR-ABL-double jeopardy? Leuk Res 2008, 32:1489-1490.